Our findings determined that rather than resulting in a partial slowing of disease progression, starting mPGES-1 inhibitor treatment on day 7 of the AngII infusion resulted in a complete disruption of further AAA progression through completion of the 28-day AngII infusion. This evidence concerns the gene AGT and triple-A syndrome.